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Introduction
Cancer is one of the leading causes of death worldwide. There 
were approximately 1.7 million new cases of cancer and over 
585,000 cancer-related deaths in the U.S. alone in 2014.1 
Around one in eight women will be diagnosed with breast 
cancer in their lifetime, and hundreds of thousands of people 
in the U.S. are diagnosed with this disease each year.2 Because 
cancer springs from the rapid growth of abnormal cells, effec-
tive early detection and screening are principal to overcoming 
this disease. Therefore, medical researchers have been con-
ducting genetic and epigenetic research to find potential bio-
markers for early detection, screening, and treatment.3–5
Traditional pathological examination of tumors tends 
to rely on needle biopsy, a procedure that analyzes tiny frac-
tions of cells that may not sufficiently represent the tumor 
mass in heterogeneous cells. This means that important dis-
ease details and features may be overlooked. Furthermore, 
increasing evidence indicates greater heterogeneity of cancer 
cells when compared to normal cells. Although some research 
has been done on cancer heterogeneity patterns using DNA 
sequencing data,6 this topic is relatively new and challenging 
because genome-wide DNA sequencing datasets are as large 
as hundreds of gigabytes or even terabytes and have complex 
biological and technical structures.7 In this paper, we focus 
on studying cancer methylation heterogeneity patterns for 
breast cancer cell lines. Detailed information about DNA 
methylation is illustrated below.
DNA methylation occurs when a methyl group (-CH3) 
covalently bonds to a cytosine in the dinucleotide 5′-CpG-3′ 
(or the fifth nucleotide).8 When a cytosine is linked to a gua-
nine by a phosphodiester bond, a CG or CpG site is formed. 
CpG islands are genomic regions that are rich in CpG sites. 
These islands often overlap with transcription start sites of 
genes, as well as intergenic regions and gene bodies.9 DNA 
methylation plays an important role in regulating gene expres-
sion by directly preventing transcription factor binding.9 DNA 
methylation near transcription starting sites may block initia-
tion and methylation in centromeres and other repeat regions. 
DNA methylation is also likely to have a role in both chromo-
somal and genome stability through suppressing expression of 
transposable elements.10
Heterogeneous or differential methylation means that 
there is a large amount of methylation variation or difference 
among different samples of one group (eg, cancer patients) 
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or between two groups (eg, cancer patients and normal 
individuals).11–14 For instance, comparing methylation ratios 
at each cytosine base (mC-ratio) in different cancer patients 
reveals heterogeneous methylation patterns. It is important to 
identify the genes or regions that have heterogeneous methy-
lation patterns across different samples or patients. Generally 
speaking, researchers are aware of the existence of methyla-
tion heterogeneity, but it is unknown what the exact heteroge-
neity patterns are. It is also unclear how many genes have such 
hetero geneous patterns and what the impact these heteroge-
neous genes may have, especially in relation to cancer genes. 
In order to address the above questions, we conduct a bioin-
formatics analysis. More detailed explanations of all steps and 
results are introduced in the following sections.
Methods
Four metrics for methylation heterogeneity analysis. 
In some genomic regions, DNA methylation levels are hetero-
geneous across different cancer patients or samples. The het-
erogeneity pattern may be due to different methylation events 
within cancer cells. In order to gain some intuitive under-
standing of the methylation heterogeneity or variation pat-
terns, we first calculate the mean and standard deviation at 
selected CpG sites across all cell lines. Our exploratory analy-
sis of mean and standard deviation of the methylation levels 
at each CpG site reveals that most CpG sites are either fully 
methylated or not at all. Moreover, there is clear evidence that 
the methylation levels at some CpG sites are much more het-
erogeneous. We also find that greater variation or heterogene-
ity is often observed in partially methylated sites. Based on 
this understanding, we choose to analyze DNA methylation 
heterogeneity patterns using four statistical metrics: variance, 
I 2 statistic, entropy score, and methylation state.
Variance. We calculate the sample variance of methylation 
levels of all samples at a CpG site and use the standard devia-
tion to measure the variation or spread of DNA methylation 
levels. Large variation indicates that the methylation levels 
of different samples are very heterogeneous. We compare the 
other two quantitative metrics (see below) with standard devi-
ation because this metric is a direct measure of variation.
I2 statistic. The I 2 statistic was originally introduced by 
Higgins et al.15,16 to measure the impact of heterogeneity on 
meta-analysis. This statistic is defined based on the Cochran’s 
heterogeneity statistic Q, that is, I Q dfQ
2 100= −



× %, where 
Q is the chi-square statistic and df is the degree of freedom. 
In this article, we borrow the idea of the I 2 statistic and use a 
slightly modified version of this statistic. Specifically, we use 
the chi-square statistic Q n s= −( )1
2
2σ
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samples at each CpG site, s2 is the sample variance, and σ 2 is a 
predetermined value with the default value of σ 2 = 0.0225 in 
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on our previous exploratory analysis and a recent publication 
on differential methylation identification.11 In the context of 
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accounting for the sample size.
Entropy score. Entropy may be used to measure the 
randomness and heterogeneity level among different samples 
and determine if methylation levels vary from person to per-
son among cancer patients. We will calculate an entropy score 
for each CpG site as defined by the method named Quantita-
tive Differentially Methylated Regions (QDMR) below.14 Let 
mi = (mi,1, mi,2, …, mi,s, …, mi,N) be the methylation levels at 
CpG site i and across N samples, where mi,s represents the 
methylation level in sample s. The sum of methylation levels of 
CpG site i in N samples is 
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methylation level m′i,s for sample s is then calculated as m′i,s = 
|mi,s – Ti,b|. Using the transformed methylation levels, QDMR 
first defines an entropy score as: H pP
s
N
i s= −
=
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′ ,  log2(p′i,s), 
where p m mi s i s
s
N
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. To account for the range of varia-
tion, QDMR introduces a methylation weight to modify the 
above HP. In particular, let max(m′i,s) and min(m′i,s) be the 
maximum and minimum methylation levels, respectively, of 
region i. Let “MAX” and “MIN” be the highest and lowest 
methylation levels, respectively. With the methylation weight, 
wi = |log2 
max min
MAX MIN
m mi s i s′ ′, ,( ) − ( )
−
+








ε  |, where ε = 0.0001 is 
used to offset the logarithmic argument, the f inal entropy 
score is defined as HQ = HP × wi. Note that because the 
above entropy score was introduced by QDMR, we use 
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notations that are very similar to the ones used in the 
QDMR paper.
Methylation state. For methylation states, we categorize 
CpG sites into the several categories: L (Low), H (High), 
M (Median), and O (Other). A low methylation state (L) 
means that all methylation levels at a CpG site are below 
0.2, and a high methylation state (H) means that all methy-
lation levels at a CpG site are above 0.8. A median methyla-
tion state (M) means that all methylation levels at a CpG 
site are between 0.2 and 0.8. The CpG sites with methyla-
tion levels that do not fall in any of these three categories 
are defined as an O (Other) state. CpG sites of the O state 
are then further categorized into Bimodal, High-Medium 
(HM) methylation, Low-Medium (LM) methylation, and 
then Rest (R). A Bimodal methylation state means that over 
40% of the samples at a CpG site have methylation levels 
below 0.2, and over 40% of the samples have levels above 
0.8. A High-Median (HM) methylation state occurs when 
all methylation levels at a CpG site are above 0.4. A Low-
Median (LM) methylation state occurs when all methylation 
levels at a CpG site are below 0.6. The remaining CpG sites 
are categorized as the Rest (R) methylation state. All meth-
ylation states are shown using example data in Figure 1. By 
categorizing the data with these classifications as shown 
in Figure 1, we can analyze the methylation heterogeneity 
patterns in more detail. Among all the above methylation 
states, we are most interested in the Bimodal and the Rest 
methylation states because they are the most heterogeneous, 
or least consistent, and therefore most likely to affect tumor 
suppressor genes and oncogenes.
data and r functions. The dataset used in this project 
contains the methylation level for each CpG site of seven 
breast cancer cell lines, namely, BT20, BT474, MCF7, 
MDAMB231, MDAMB468, T47D, and ZR751. The DNA 
methylation sequencing data of these seven samples are publicly 
available (GSE27003).17 The data preprocessing step is done 
using the methylation sequencing alignment tool BRAT-bw.18 
From our preliminary study, we know that cancer methylation 
levels are more heterogeneous than normal data.12 Abnormal 
heterogeneous methylation patterns may cause the silencing of 
tumor suppressor genes and the overexpression of oncogenes. 
Before any statistical analysis, we process our data by extract-
ing the CpG sites with methylation levels for more than 70% 
of the samples for better accuracy.
Genome datasets are enormous, and it takes time to 
process them. In order to analyze and interpret DNA meth-
ylation sequencing data, we have used the statistical com-
puter language R to analyze heterogeneity patterns for DNA 
methylation sequencing data. To speed up the analysis, we have 
used a high-performing super computer with multiple nodes for 
parallel processing. With the obtained output files, we then run 
other programs to process further information, such as obtain-
ing a list of genes that cover selected heterogeneous CpG sites.
results
Performance of four metrics. In the last section, we 
illustrated the performance of the four metrics that we use 
to study methylation heterogeneity or variation levels. Among 
these four metrics, methylation state is the most intuitive one. 
Based on the definition of the different methylation states, 
CpG sites with High (H) and Low (L) methylation states have 
low variation, whereas Median (M) and Other (O) methylation 
states show more variation, which is expected. The methyla-
tion state of one chromosome (chr1) is summarized in Table 1. 
From Table 1, we can see that the High (H) and Low (L) 
states together contribute about 55% (16.33% + 38.13%) of the 
CpG sites. The High-Median (HM) and Low-Median (LM) 
states together contribute to about 17% (11.83% + 5.22%) of 
the CpG sites. The Median (M) state has the least number 
of CpG sites (only 0.19%). About 2% of CpG sites have the 
Bimodal pattern. The Rest state has about 26.32% of the total 
sites. CpG sites with the Rest state are heterogeneous but lack 
patterns, making it difficult to categorize them specifically. 
Among the seven methylation states, Bimodal and Rest have 
most heterogeneous patterns.
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figure 1. Dot plot of methylation states.
table 1. number and percentage of CpG sites belonging to each 
methylation state.
MetHYLAtIoN 
StAte
NuMBeR of 
Cpg SIteS
PeRCeNtAge of 
totAL Cpg SIteS
Bimodal 2106 1.98%
High 17362 16.33%
High-Median 12575 11.83%
Low 40541 38.13%
Low-Median 5548 5.22%
Median 205 0.19%
Rest 27980 26.32%
total 106317 100.00%
Notes: the summary is done for chromosome 1, but the percentages 
are representative of the entire genome. methylation states are shown in 
alphabetical order.
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Because the qualitative metric (methylation state) is the 
most intuitive and biologically meaningful metric, we plot 
the three quantitative metrics: standard deviation, I 2 statis-
tic, and entropy score against each methylation state using 
boxplots (Fig. 2). These plots will help us analyze how well 
each quantitative metric measures heterogeneity level. The 
two metrics standard deviation and I 2 statistic produce very 
similar representations of heterogeneity. However, it is evi-
dent that entropy does not produce an analogous result. We 
then compare the entropy score with standard deviation using 
a plot with different methylation states highlighted with dif-
ferent colors (Fig. 3). Figure 3 shows that the entropy score 
nearly reverses the relative variation pattern for some CpG 
sites: High (H) and Low (L) methylation states show greater 
heterogeneity, while Median (M) and other methylation states 
show lower heterogeneity. That is, Figure 2 shows a different 
pattern when comparing entropy with standard deviation, and 
this pattern is counterintuitive.
When the I 2 statistic versus the standard deviation is 
graphed, there is a clear positive correlation between the two 
metrics (Fig. 4). The CpG sites categorized as High (H) or 
Low (L) have very low I 2 values, which are expected because 
the methylation levels in these categories have a very narrow 
range for the values to fall into. Furthermore, the Bimodal and 
Rest states have high I 2 statistic values. CpG sites that have a 
methylation state considered to be Bimodal or Rest are actually 
far more heterogeneous. As Table 1 shows, Bimodal and Rest 
states together hold a significant percentage (about 28.3% of 
the data) of CpG sites in each chromosome.
As shown above, the entropy score gives a different and 
counterintuitive result. However, variance (or standard devia-
tion), I 2 statistic, and methylation state all give relatively intu-
itive and similar measures of heterogeneity or variation. These 
BiModal H HM L LM M Rest
0.5
0.3
0.4
0.4
0.6
0.8
0.2
0.2
0.1
S
ta
n
d
ar
d
 d
ev
ia
ti
o
n
I-
sq
u
ar
e
E
n
tr
o
p
y
Methylation state
BiModal H HM L LM M Rest
Methylation state
BiModal H HM L LM M Rest
Methylation state
Standard deviation vs. methylation states
I-square vs. methylation states
Entropy vs. methylation states
0.0
0.0
0
5
10
15
20
figure 2. Boxplots of quantitative metrics vs. methylation states.
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figure 3. a scatterplot of entropy against standard deviation.
0.8
H
HM
Bimodal
LM
M
Rest
L
0.6
0.4
0.2
0.0
0.0 0.1 0.2 0.3 0.4
Standard deviation of CpG sites
I2 statistic vs. standard deviation
I2
 s
ta
ti
st
ic
 p
f 
C
p
G
 s
it
es
0.5
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three metrics could be considered for measures of variability 
or heterogeneity across samples. For the rest of the section, 
we use the intuitive metric (methylation state) to consider the 
biological implication that heterogeneous genes may have on 
breast cancer.
biological implications based on genetics and pathway 
analysis. Genetic analysis. Because we are specifically interested 
in the genes with highly heterogeneous methylation patterns, 
we select the CpG sites that are categorized as Bimodal and 
Rest methylation states. We utilize an R function written by 
Dr. Sun’s laboratory to annotate our processed breast cancer 
data, generating two lists of genes with CpG sites in the body 
or in the promoter region. These lists are combined and repeats 
are omitted. We then obtain a variable that is the number of 
heterogeneous CpG sites associated with each gene. When 
checking the distribution of this variable, we find that this list 
of numbers ranges from 1 to 112 and that 75% of these num-
bers are not larger than 3. In order to ensure that the selected 
genes are of greater importance in relation to breast cancer, we 
have specified parameters in our code to select only the genes 
with over 25 heterogeneous CpG sites. With this selection, we 
further analyze the top 13.5% of heterogeneous genes. Using 
this particular list of genes, we utilize the ConsensusPath 
Database (ConsensusPathDB)19–21 to integrate interaction 
networks among genes, creating genetic maps for visualiza-
tion of our heterogeneous gene lists. In the entire genome of 
breast cancer data from the 7 cell lines, there are 2618 dis-
tinct genes with at least 25 heterogeneous CpG sites that are 
categorized as the most heterogeneous methylation states, 
Bimodal and Rest. A total of 710 of these genes are related to 
cancer modules22 (ie, cancer-related gene sets). We then use 
these genes in our further analyses. These cancer modules are 
identified by mining a large compendium of cancer-related 
microarray data.22 To determine the link between our signifi-
cant genes and their biological importance, we compare them 
to lists of breast cancer methylated genes, tumor suppressor 
genes, oncogenes, and transcription factors. This comparison 
indicates that of our specified gene list, 43 are known breast 
cancer methylated genes, 5 are tumor suppressor genes, 81 
are oncogenes, and a significant 376 are transcription factors. 
Moreover, 44 of these transcription factors are also identified 
as oncogenes; therefore, if expressed, they may have a high 
impact on tumor growth.
We further analyze our 2618 genes with heterogeneous 
CpG sites and their biological significance by utilizing the 
gene set enrichment analysis (GSEA) that was created by the 
Broad Institute of MIT and Harvard.23 This GSEA software 
package uses a hypergeometric distribution to compare our 
list of heterogeneous genes with gene lists found in Molecu-
lar Signatures Database, a collection of annotated gene sets. 
To ensure statistical significance, we use the GSEA default 
FDR (False Discovery Rate) q-values ,0.05. Using “can-
cer modules” as “gene sets”, our GSEA analysis shows that 
with q-values less than 0.05, at least 173 genes are overlapped 
or significantly represented in the top 10 cancer modules. 
Examination of gene sets and their overlap can highlight 
common biological processes. Among 173 hetero geneous 
genes, 15 significantly represent in the top 10 cancer mod-
ules (Table 2). Detailed descriptions of these 15 genes can be 
found online in GeneCards (www.genecards.org). The num-
bers of the top cancer modules are listed in Table 2. These 
modules are gene sets that are significantly changed in various 
cancer conditions.22 More detailed description of these cancer 
modules can be found online.24 In addition, instead of using 
cancer modules as “gene sets”, we may use the KEGG path-
ways as “gene sets” for the GSEA. Using the KEGG pathway 
for GSEA, important KEGG cancer pathways and signaling 
pathways (eg, MAPK signaling pathway and calcium signal-
ing pathway) are significantly represented.
Tumor suppressor and breast cancer-related genetic pathways. 
Using the carefully chosen list of heterogeneous genes, we 
select 173 genes that are significantly represented in numer-
ous important cancer modules to determine potential links 
between certain genes in our list and the genes related to breast 
cancer. Utilizing the genetic software, ConsensusPathDB, we 
have created an induced network module as shown in Figure 5, 
considering only high-confidence binary protein and gene 
regulatory interactions to ensure the importance of the genes’ 
roles in relation to breast cancer. In addition to the selected 
heterogeneous genes of high-confidence relation, we have also 
included genes that regulate the cell cycle, tumor suppression, 
transcription factors, and cell reception, which are frequently 
linked with breast cancer. Abnormal methylation of these 
genes may lead to tumorigenesis. In order to include these 
genes, we first take a list of genes that are typically linked with 
table 2. fifteen heterogeneous sample genes represented in top 
10 significant cancer modules.
geNe 
SYMBoL
CANCeR MoDuLe ID
100 66 137 11 220 47 12 41 88 55
PDGfra X X X – X – X X X X
DPYsL3 X X X X X X X – – –
sPoCK1 X X X X X X – – – –
tfaP2B X X X X X – X X X X
PaX6 X X X X X – X X X X
soX9 X X X X X – X – X X
feZ1 X X X X X – X – – –
ntrK2 X X X X X – X – – –
CrmP1 X X X X X – X – – –
KaL1 X X X X X – X – – –
neUrL X X X X X – – X X X
nrG2 X X X X X – – X X X
DPYsL4 X X X X X – – X X X
tBr1 X X X X X – – X X X
CBLn1 X X X X X – – X – –
Note: “X” indicates that the gene exists in the cancer module.
Tian et al
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breast cancer and then add them to the list of heterogeneous 
genes before running the ConsensusPathDB. By including 
genes that have known links to breast cancer in the network, 
the ability to identify a novel gene from the list of heteroge-
neous genes that is linked to breast cancer may increase. That 
is, genes that are more connected to or share pathways with 
a large number of genes such as oncogenes and tumor sup-
pressor genes are also more likely in general to be linked with 
breast cancer, and thus, the genes that are deeply rooted in the 
network of known cancer-related genes may also be novel bio-
markers or cancer genes. In particular, as shown in Figure 5, 
the TP53 gene is a tumor suppressor protein containing DNA 
binding and transcriptional activation domains. TP53 inter-
acts both indirectly and directly with many of our selected 
genes. The TNF-alpha gene is a tumor necrosis factor involved 
in a wide spectrum of biological interactions, and it is mostly 
indirectly connected to our selected heterogeneous genes.
Beyond the above tumor suppressor genes, we have 
also formed genetic mappings between the heterogeneous 
gene list of 173 and known breast cancer genes of high- or 
intermediate-risk such as BRCA1, BRCA2, STK11, PTEN, 
ATM, CHEK2, MRE11A, RAD50, and NBN.25–27 Breast 
cancer cases are usually associated with these abnormal genes. 
We have limited the number of breast cancer genes by choos-
ing those with the most evidence of their relation to cancer. 
Implementing the induced network module once again, we 
consider binary protein and gene regulatory interactions to 
determine biological links between our long list of poten-
tial breast cancer biomarkers and these known cancer genes. 
From this network, we notice a multitude of heterogeneous 
genes directly linked to high-risk breast cancer genes, espe-
cially those in the top right section of Figure 6. Abnormalities 
in these genes are likely to affect gene and protein interac-
tions and biological functions, thus giving a high potential for 
affecting and indicating breast cancer in a patient.
Hub genes and potential biomarkers for breast cancer. By 
selecting heterogeneous genes that show up most signifi-
cantly in a greater number of cancer modules, we obtain a 
longer list of 271 genes. We then remove intermediate nodes, 
focusing only on the original data to discover hub genes as 
shown in Figure 7. In Figure 7, the number of interactions 
ranges from 1 to 8. We define hub genes as heterogeneous 
oncogenes that interact with six other genes. Therefore, we 
select approximately the top 25% of interactive genes, which 
likely lead to greater potential consequences due to increased 
relations. Genes that indicate potential effects in multiple 
cancer modules are more likely indicators of the breast cancer 
itself. In Figure 7, 12 indicated oncogenes are found among 
our prespecified heterogeneous genes. We notice that 6 of 
these 12 (or 50%) oncogenes are identified as hub genes. The 
Node lable color
 black node labels denote
 seed nodes;
 purple node labels denote
 intermediate nodes
Physical entity color
Gene
Protein
Protein complex
RNA
Compound
Protein interaction
Genetic interaction
Biochemical reaction
Gene regulatory interaction
Interaction color
figure 5. tumor suppressor gene network including tP53, tP63, and tnf-alpha.  
Notes: the three genes (tP53, tP63, and tnf-alpha) are outlined in red. Black node labels represent heterogeneous genes. Blue node labels represent 
intermediate genes or proteins.
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Node lable color
 black node labels denote
 seed nodes;
 purple node labels denote
 intermediate nodes
Physical entity color
Gene
Protein
Protein complex
RNA
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Protein interaction
Genetic interaction
Biochemical reaction
Gene regulatory interaction
Interaction color
figure 6. Breast cancer susceptibility of high- and intermediate-risk genetic mapping.  
Note: these breast cancer genes are outlined in red.
Physical entity color
Gene
Protein
Protein complex
RNA
Compound
Protein interaction
Genetic interaction
Biochemical reaction
Gene regulatory interaction
Interaction color
figure 7. networks for hub genes and potential biomarkers for breast cancer.  
Notes: all known oncogenes that are part of our heterogeneous list are outlined in red. Highly interactive hub genes are outlined in black.
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hub genes may have strong potential as breast cancer bio-
markers and are listed along with their functions in Table 3. 
Our results show a relatively strong correlation between 
hetero geneous oncogenes in breast cancer cell lines and their 
roles as hub genes.
discussion
We focus part of our research on the comparison of metrics 
both quantitatively and qualitatively. It is intuitive that the 
qualitative methylation states of H, L, HM, and LM have 
relatively less variation than the Median, Bimodal, and Rest 
states, but it is not quantitatively clear how large the variation 
of reach methylation state is and how different several methy-
lation states are. In addition, as shown in the QDMR paper, 
the entropy seems to be a good method of identifying differ-
ential methylation regions or characterizing the heterogeneity 
patterns of methylation levels. However, when we zoom in 
to investigate the performance of the entropy score, we find 
the surprising and counterintuitive results of QDMR entropy. 
This has sparked our interest in evaluating other quantitative 
metrics and comparing them with the intuitive qualitative 
metric of methylation states, as shown in Figure 2.
As for methylation states, we define them based on our 
understanding of the methylation sequencing data. We did 
some exploratory analysis as shown in Figure 1 of our previous 
publication at the International Journal of Biomedical Data 
Mining.12 According to Figure 1 and in theory, the Low (or L) 
methylation state should be around “0”. In addition, consider-
ing that there may be methylation sequencing quality issues 
and large variation due to unknown reasons, we define it to be 
[0, 0.2]. Similarly, we define the High (or H) methylation state 
to be in the range of [0.8, 1].
Methylation, as a component of normal cellular ontogeny, 
likely plays a critical role in facilitating tumor cell progression. 
Because methylation, especially hemimethylation (methylation 
only on one DNA strand28), can be ephemeral in nature, it is 
sometimes used to explain sudden changes in metastatic abili-
ties. Variation in DNA methylation, which is related to eukary-
otic gene control, may play a major role in the hetero geneity and 
phenotypic instability found in cancer cells. Random somatic 
mutational events, which are responsible for heterogeneity and 
are exemplified by the Bimodal and Rest methylation states, 
could reinforce increasingly malignant tumor cells and less 
responsive states due to increasing genetic alterations.29 In addi-
tion, increased epigenetic heterogeneity in cancer could support 
cancer cells in rapidly adapting to changing environments.30
conclusion
In this paper, we have studied the methylation heterogeneity 
patterns for breast cancer cell lines by comparing four met-
rics: variance, I 2 statistic, entropy score, and methylation state. 
After performing a comparative analysis on the effectiveness 
of each metric, we have used the categorical metric (methy-
lation state) to extract genes with the most heterogeneous 
states (namely, Bimodal and Rest), which we run through 
the GSEA software to sort the genes in relation to cancer 
modules.22 We have compared the list of Bimodal and Rest 
heterogeneous genes with numerous data sets to determine the 
number of known breast cancer methylated genes, tumor sup-
pressor genes, oncogenes, and transcription factors found in 
the heterogeneous gene list. A significant number (376) of the 
entire gene list is transcription factors. Moreover, 44 of these 
transcription factors are also identified as oncogenes; there-
fore, if expressed, these genes may have a high impact on 
cancer development.
table 3. Carefully selected heterogeneous hub genes from cancer 
modules.
geNe HuB DeSCRIPtIoN of geNe
nCam1 encodes a protein that is involved in cell-to-cell inter-
actions and development and differentiation
NTRK1 oncogene; encodes a member of the ntrK family; 
mutations in this gene have been linked to cancer
NTRK2 oncogene; encodes a member of the ntrK family 
that leads to cell differentiation; mutations have not 
been linked to cancer
FGFR2 oncogene; Protein coding gene; mutations linked to 
various syndromes
FGFR3 oncogene; Protein coding gene; mutations linked to 
dwarfism
DCLK1 encodes a protein that is linked to neurogenesis and 
neuronal apoptosis
PrKCB Protein coding gene; serves as a receptor for a 
class of tumor promoters
PDGFRA oncogene; Protein coding gene; Plays a role in 
tumor progression; mutations have been linked with 
a variety of cancers
TLX1 oncogene; encodes a nuclear transcription factor; 
Linked to leukemia
sH3GL2 Protein coding gene; related to identical protein 
binding and lipid binding
sH3GL3 Protein coding gene; related to identical protein 
binding and lipid binding
sPeG Protein coding gene; Lack of this protein affects 
myocardial development
PrKCZ Protein coding gene; not a receptor for phorbol 
ester, tumor promoters
ror2 Protein coding gene required for cartilage and 
growth plate development
fHL1 Protein coding gene; mutations linked with muscular 
dystrophy
CDH2 encodes a protein required for establishment of left-
right asymmetry
fLt1 Protein coding gene; related diseases include 
microcystic meningioma
ePHB1 encodes a protein that mediates developmental 
processes
ePHB2 encodes a protein that mediates developmental pro-
cesses; related diseases include various cancers
Notes: the genetic functions of these genes are provided in the second 
column. six known heterogeneous oncogenes are in italic. these hub genes 
have significant potential as indications of breast cancer susceptibility.
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After selecting genes represented in the highest number 
of related cancer modules, we have utilized the publicly avail-
able software ConsensusPathDB to analyze integrated gene 
networks. These networks display significant selected hetero-
geneous genes that are linked in biological functions to tumor 
suppressor genes and high- and moderate-risk known breast 
cancer genes. Furthermore, we merge our results from GSEA 
and ConsensusPathDB to determine a link between hetero-
geneous oncogenes and hub genes, or genes that interact with 
at least six separate genes from the cancer modules. There-
fore, the more cancer modules in which a gene has effect, the 
stronger its indication of breast cancer. Using this information, 
we conclude that a considerable percentage of heterogeneous 
known oncogenes are also hub genes, determining 19 poten-
tial breast cancer biomarker genes. These 19 genes are a contri-
bution to the genetic databases PubMeth (pubmeth.org) and 
GeneCards (genecards.org), as well as cancer treatment and 
screening for early detection among breast cancer patients.
Our results provide a substantial contribution to the 
growing databases of breast cancer-related genes, which can 
be used during early treatment and screening of patients to 
discover certain genes that may have an important impact on 
breast cancer. Our results also show a significant correlation 
between heterogeneous oncogenes and hub genes (the poten-
tial biomarkers) that other cancer researchers and doctors may 
find useful when locating cancerous genomic regions.
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